Last reviewed · How we verify
NCT04009642: CardioMET
Cardiac Rest and Stress Metabolism in Patients With Type 2 Diabetes
trial testing Surely observational based on disease state in Diabetes Mellitus, Type 2 in 8 participants. Completed in 1 March 2020.
1 March 2020
Quick facts
| Lead sponsor | University of Leicester |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 8 |
| Start date | 5 March 2018 |
| Primary completion | 1 March 2020 |
| Estimated completion | 1 March 2020 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Surely observational based on disease state
Conditions studied
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
- Metabolic Cardiomyopathy — all drugs for Metabolic Cardiomyopathy →
- Metabolic Disturbance — all drugs for Metabolic Disturbance →
- Fatty Acid Oxidation Disorder — all drugs for Fatty Acid Oxidation Disorder →
Sponsor
University of Leicester
Who can join
18 and older, any sex, with Diabetes Mellitus, Type 2 or Metabolic Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The number of people with diabetes is rising. One of the major causes of premature death in diabetes is heart failure (HF). This is when the heart cannot pump blood effectively, and this may be related to abnormalities in energy production in the heart muscle. In healthy people, the heart muscle cells show flexibility and can use both sugar and fat molecules for energy production. Although burning fat provides more energy, this process requires more oxygen than burning sugars. As a result, fat is a less efficient fuel for the heart compared to sugars, especially in situations where the energy and oxygen needs are higher, such as during exercise. The investigators propose that the heart muscle in patients with type 2 diabetes relies heavily on fat for energy provision, and fails to burn more sugar molecules for energy provision during exercise to more efficiently use oxygen. Fat and sugar uptake by the heart can be detected by the difference between the blood sugar and fat levels delivered to the heart and returning from the heart, both at rest and also when the heart is working faster during Dobutamine infusion. Dobutamine is a drug frequently used to mimic exercise, and get the heart running faster during medical tests. To test the hypothesis, the investigators will assess fat and sugar uptake by the heart at rest and when the heart is running faster, in patients with type 2 diabetes undergoing investigations to rule out coronary disease. Heart function, and blood supply to heart muscle, at rest and during Dobutamine infusion, will also be measured using MRI scanning. The same tests will be performed in people without diabetes for comparison. It will help understand diabetic heart disease and which aspects may be targeted with new treatments.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04009642
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
- NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
Other University of Leicester trials
Trials by the same sponsor.
- NCT07389785 — Age Related Chromatin Remodelling as a Therapeutic Target for Organ Protection in Cardiac Surgery · active not recruiting
- NCT07014579 — Using Heart Electrical Signals to Study How Well Treatments Prevent Dangerous Heart Rhythms in Active People · not yet recruiting
- NCT06955663 — Exercise Support and Rehabilitation for Patients After Spontaneous Coronary Artery Dissection · NA · recruiting
- NCT06629675 — Make Every Step Count: Personalised Music Feedback to Walking for People Living With COPD · NA · recruiting
- NCT06844656 — Understanding the Increased Risk of Atrial Fibrillation in Athletes: a Case-control Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04009642 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Leicester
- Last refreshed: 3 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04009642.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing